Technology ID

SARS-CoV-2 Neutralizing Nanobodies for Therapeutic and Diagnostic Uses

Lead Inventor
Casellas, Rafael (NIAMS)
Xu, Jianliang (NIAMS)
Research Materials
Therapeutic Areas
Infectious Disease
Development Stages
Pre-clinical (in vivo)
Research Products
Animal Models
Lead IC

This technology involves the utilization of highly effective nanobodies, specifically camelid antibodies, derived from immunized llamas to neutralize SARS-CoV-2. Additionally, it employs a unique mouse model, called a "nanomouse," that is engineered to express antibody genes from camels, alpacas, and dromedaries. These nanobodies offer significant advantages over traditional human and mouse antibodies due to their smaller size, which allows them to effectively target and bind to specific areas on antigens. The primary applications of this technology are twofold: therapeutically, to inhibit COVID-19 in patients, and diagnostically, to detect the presence of the infection in blood samples using methods like ELISA. This innovative approach holds promise for both treating and identifying COVID-19 more effectively.

Commercial Applications
Potential applications include blocking COVID-19 in patients and detecting the virus in blood samples, using methods such as ELISA or similar diagnostic techniques.

Competitive Advantages
The competitive advantage of this technology lies in its use of small, highly effective nanobodies from camelids, which can access antigen crevices that conventional human and mouse antibodies cannot, enhancing their potential for COVID-19 treatment and detection.
Licensing Contact:
Knezevic, Vladimir